Author:
Alamer Ahmad,Almutairi Abdulaali R.,Halloush Shiraz,Al-jedai Ahmed,Alrashed Ahmed,AlFaifi Mashael,Mohzari Yahya,Almutairi Malak,AlHassar Fatimah,Howaidi Jude,Almutairi Wedad,Abraham Ivo,Alkhatib Nimer
Subject
Pharmaceutical Science,Pharmacology
Reference21 articles.
1. Adis Insight: Favipiravir 2020 https://adisinsight.springer.com/drugs/800014667. Accessed on 6 November 2022.
2. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis;Alamer;Curr. Med. Res. Opin.,2021
3. Decision Modelling for Health Economic Evaluation;Brigggs,2006
4. Experimental treatment with favipiravir for COVID-19: an open-label control study;Cai;Engineering (Beijing),2020
5. Favipiravir versus arbidol for clinical recovery rate in moderate and severe adult COVID-19 patients: a prospective, multicenter, open-label, randomized controlled clinical trial;Chen;Front. Pharmacol.,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献